Hematology Advisor

HRQoL Complements Clinician Reports in Assessing the Use of Pola-R-CHP in Previously Untreated DLBCL Researchers determined HRQoL can play a complementary role to clinician-reported AEs to more fully represent the efficacy and tolerability of Pola-R-CHP in DLBCL.

Clinical Snapshot: #DLBCL QoL Reporting 📊

• Data: Clinicians underreport symptoms vs patients (Kappa 0.16–0.44).
• Impact: Leads to inaccurate risk assessments.

From @bloodjournals.hematology.org. Read: https://bit.ly/4u2XCuL

#HemeOnc #lymsm

With #HemeOnc evolving rapidly, educators must integrate new developments into clinical frameworks. @s-brond.bsky.social (@ucsfhealth.bsky.social) discusses novel strategies in @ascopost.bsky.social.

Details: https://bit.ly/4qYy2Ei

#MedEd #Oncology

DTI-ALPS Index Shows Promise as a Neuroimaging Biomarker in Beta-Thalassemia Major Researchers determined the DTI-ALPS index shows potential as a neuroimaging biomarker for assessing glymphatic dysfunction and cognitive impairment in β-thalassemia major.

Clinical Snapshot: Neuroimaging in Beta-#Thalassemia 📊

• Data: ALPS index significantly lower in patients vs controls (P < .001).
• Finding: Strong correlation between cognitive scores and ALPS index.

Read the review: https://bit.ly/4cafCwE

#HemeOnc #Hematology

FDA Grants Priority Review to Iberdomide for Multiple Myeloma The FDA accepted for Priority Review the New Drug Application for iberdomide in the treatment of patients with relapsed or refractory multiple myeloma.

@fda.gov grants Priority Review to iberdomide for R/R #multipleMyeloma:

• Novel oral cereblon E3 ligase modulator
• 44.5% overall response rate
• 3.9 months median time to response

From @medicalprofref.bsky.social. Read more: https://bit.ly/4cnoOOv

#Hematology #FDA #ClinicalTrials

Isatuximab Demonstrated Promising Efficacy in R/R Light Chain Amyloidosis Researchers determined isatuximab monotherapy resulted in promising hematologic response rates with a good safety profile among patients with R/R AL amyloidosis.

Isatuximab monotherapy shows significant clinical activity in R/R AL #amyloidosis:

• 77.1% overall hematologic response rate
• 1.1 months median time to response
• 57% cardiac response rate

From @bloodjournals.hematology.org Read more: ➡️ https://bit.ly/4qNGBBR

#Hematology #ClinicalTrials #MedSky

Improved Early Post-Transplant Recovery, HRQoL Observed With Orca-T - Hematology Advisor Researchers sought to determine whether Orca-T would lead to earlier recovery following transplant and better HRQoL compared with conventional alloHSCT.

- Orca-T shows faster recovery vs SOC.

- Median: 12 vs 13 days (neutrophils); 12 vs 17 days (platelets).

- Improved physical/mental health at day 180.

- Data from #Tandem26 via @astct.bsky.social @cibmtr.bsky.social.

Read the review: https://bit.ly/3OyOmOx

#Hematology #HCT #CellTherapy

Axatilimab Plus Ruxolitinib May Be a Safe Combination Against Newly Diagnosed GVHD - Hematology Advisor Researchers sought to determine whether combining axatilimab and ruxolitinib is a safe strategy among patients with newly diagnosed chronic GVHD.

REVEAL study: Axatilimab + ruxolitinib achieved 69% ORR in R/R #cGvHD. 🩺

60% of patients reported ≥1 Grade 3 TEAE.

20.5% experienced Grade 4.

Findings from #Tandem26 via @astct.bsky.social @cibmtr.bsky.social

Read the review: https://bit.ly/4cyLJ9o

#Hematology #GvHD #MedicalNews

Emicizumab Prophylaxis May Be Safe, Effective in Infants With Hemophilia A Emicizumab prophylaxis was considered potentially safe and effective in a real-world, international study of infants with hemophilia A.

Emicizumab reduced mean ABR from 11.48 to 0.05 over 12 months.

71% of patients remained bleed-free compared to 35% at baseline.

Target joint bleeding decreased by 82% during the study period.

Read the review: https://bit.ly/4c2doPQ

#Hematology #HemophiliaA #ClinicalData #PrecisionMedicine

CHIP Significantly Associated With Heart Failure Researchers determined CHIP is associated with incident heart failure.

Clonal hematopoiesis associated with 20.3% 10-year HF risk vs 14.5% in non-carriers.

- Ischemic CVD risk: 25.3% vs 18.5%.

- Risk amplified in patients receiving ≥7 chemotherapy cycles.

With @jamacardiology.com. Read more: ➡️ https://bit.ly/46XA7cm

#Hematology #CardioOncology #CHIP #HeartFailure

Oncology Nurses in All Roles: Be part of the community that's driving practice change and elevating patient care. Attend 11th Annual ONA Summit on March 20-21 and earn free #CE. Register here: https://bit.ly/4qjckL5

Creating a Core Set of Outcomes for Family-Centered Care in Neonatal Settings The findings from this analysis provide evidence for a more consistent, meaningful assessment of family-centered care research and practice in the neonatology setting.

The findings from this analysis provide evidence for a more consistent, meaningful assessment of family-centered care research and practice in the #neonatology setting. From @rarediseaseadvisor.bsky.social.

https://bit.ly/4qFiu8r

Yescarta Limitations of Use Removed for Primary CNS Lymphoma Based on phase 1 safety data, the FDA has removed the Limitations of Use for Yescarta in patients with relapsed or refractory primary CNS lymphoma.

The @fda.gov has approved updated labeling for Yescarta® (axicabtagene ciloleucel), removing the Limitations of Use statement for patients with R/R primary central nervous system #lymphoma. From @medicalprofref.bsky.social.

https://bit.ly/3MtH6D1

#lymsm

Real-Word Population Further Validates CAR-HEMATOTOX for CAR-T Therapy Utilizing the CAR-HEMATOTOX score among patients with R/R LBCL was reaffirmed in a larger, real-world cohort with respect to neutropenia.

Risk stratification for risk of neutropenia, infections, and survival outcomes using CAR-HEMATOTOX score among patients with R/R LBCL receiving CAR T-cell therapy was reaffirmed in a larger, real-world cohort. Published in @bloodjournals.hematology.org.

https://bit.ly/4cmEMbk

#lymsm #lymphoma

Elevated Lymphocyte-to-Monocyte Ratio May Predict Poor Outcomes in MDS Among patients in the high L/M group, transcriptomic profiling of diagnostic marrow samples revealed downregulation of inflammatory pathways and the TP53 pathway, alongside enrichment of MYC targets.

An elevated L/M ratio at diagnosis may independently predict inferior outcomes in #myelodysplasticSyndromes, although this adverse impact may be overcome by allo-HSCT. Published in @rarediseaseadvisor.bsky.social.

https://bit.ly/4bpiF3D

#MDS

Financial Factors Affect Cancer Patients' Enrollment in Clinical Trials Patients' financial resources affect their enrollment in oncology clinical trials to a greater degree than traditional demographic characteristics.

Patients’ #financial resources affect their enrollment in #oncology #clinicaltrials to a greater degree than traditional demographic characteristics. Published in @cancertherapyadv.bsky.social.

https://bit.ly/3NRdKi7

#cancertrials

Real-World Use of Efanesoctocog Alfa Shows Benefit in Severe Hemophilia A Efanesoctocog alfa improves hemostasis, reduces bleeding, and enhances quality of life for patients with severe hemophilia A, including those previously excluded from trials.

Efanesoctocog alfa has been successfully integrated into clinical practice for treating severe #hemophilia A, including patients previously excluded from trials, such as those with FVIII inhibitors or prior emicizumab use. From @rarediseaseadvisor.bsky.social.

https://bit.ly/4k5pkCc

#hemonc

Resistance Exercise Aids Physical and Mental Health Following COVID-19 Infection A personalized 3-month resistance exercise program improved walking distance and HRQOL in adults with persistent COVID-19 symptoms.

A 3-month resistance exercise intervention improves walking distance, #HRQOL, symptoms of anxiety and depression, and grip strength among adults with lingering symptoms following #COVID19 infection. Published in @jamanetworkopen.com and @infectiousdisease.bsky.social.

https://bit.ly/45yr2q2

Register today for the 11th Annual ONA Summit. Free live virtual #CE event March 20-21. Dynamic and interactive presentations led by expert faculty. Designed for #Oncology nurses in all roles. https://bit.ly/4qjckL5

Cord Blood Transplantation Shows Superior Survival for MDS The uldMTX regimen may strike an optimal balance, preserving a potent graft-versus-leukemia effect while mitigating the treatment-related toxicities that can delay engraftment or increase non-relapse mortality.

Umbilical cord blood transplantation, combined with uldMTX as a GVHD prophylaxis, provides superior survival for patients with high-risk #MDS and #AML. Published in @rarediseaseadvisor.bsky.social.

https://bit.ly/4k6jyR3

#leusm

CNI vs Belimumab for Lupus Nephritis May Carry Higher Cancer Risk Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs belimumab.

“These findings align with prior mechanistic research demonstrating increased CNI-related #cancerrisk and represents novel comparative safety data between these treatment modalities,” @jeffsparks.bsky.social of @harvardmed.bsky.social wrote.

https://bit.ly/4bqSrhm

#HemOnc

MUC4 Mutations Linked to Elevated Risk for Thrombosis in Patients With PNH The incidence of thrombotic events was statistically significantly greater among patients with MUC4 gene mutations compared with those without MUC4 mutations (P =.003).

The presence of MUC4 genetic mutations significantly increases the risk for developing thromboses in individuals with #paroxysmalNocturnalHemoglobinuria. Published in @rarediseaseadvisor.bsky.social.

https://bit.ly/3Z2nnx1

#PNH

Cancer Survivors With Lower SES Find Return to Work More Challenging Socioeconomic status of cancer survivors or the neighborhood in which they live has a significant effect on their perceived work ability and functional outcomes. Cancer survivors with low socioeconomic status or who live in low SES neighborhoods need in...

Interventions may be necessary to reach #cancersurvivors in neighborhoods with low #socioeconomic status to help them be able to successfully return to work. Published in @oncologynurseadv.bsky.social.

https://bit.ly/469EPU1

New AL-ISS Model Validated for Prognosis in AL Amyloidosis Researchers developed and externally validated the AL International Staging System (AL-ISS), a new system for staging of systemic AL amyloidosis.

A new system for staging of systemic AL #amyloidosis, the AL International Staging System (AL-ISS) was developed and externally validated in a study with findings reported in @ascopost.bsky.social Journal of Clinical Oncology.

https://bit.ly/3NJDvRt

EnzySystem Shows Promising Results in Hemophilia Testing Patients favored using the system at home, especially for self-monitoring, while healthcare professionals supported both home and clinic use.

A new point-of-care platform is gaining attention as a promising tool to improve #coagulation testing for people with #hemophilia A. From @rarediseaseadvisor.bsky.social.

https://bit.ly/462BmXm

#HemOnc

Questionnaire Assesses Issues Relevant to Adolescents/Young Adults With Cancer Researchers developed a 30-item questionnaire to measure health-related quality of life of adolescent and young adult patients with cancer. Researchers developed a 30-item questionnaire to measure health-related quality of life of adolescent and young a...

A specially designed, age-appropriate, cross-cultural questionnaire can be useful in assessing the health-related quality of life in adolescents and young adults with #cancer. Published in @jamanetworkopen.com.

https://bit.ly/4qL0vOM

#HRQOL #AYACancer

Ethics-Based Guidelines Fundamental to Clinical Trials Involving Pregnant Women Ethical considerations in research should always prioritize the well-being of the fetus and the pregnant mother.

Ethical considerations in research should always prioritize the well-being of the fetus and the #pregnant mother. From @rarediseaseadvisor.bsky.social.

https://bit.ly/45BCp0l

#ClinicalTrials

CD20-Targeting Bispecific Antibodies May Be Effective in Patients With DLBCL in Real-World Settings Researchers determined epcoritamab and glofitamab may be effective in treating patients with relapsed or refractory DLBCL in the real-world setting.

CD20-targeting bispecific antibodies including epcoritamab and glofitamab may be effective against R/R #DLBCL in the real-world setting, though survival rates were lower than those noted in pivotal clinical trials. Published in @bloodjournals.hematology.org.

https://bit.ly/3ZFUiYc

#lymsm

Patients With Terminal Blood Cancer Stress Need for Transfusion Access in Hospice Care, Survey Finds Survey results showed patients with hematologic cancers eligible for hospice care prioritize access to transfusion over other services.

Patients with #bloodcancer eligible for #hospice care emphasize the importance of access to #transfusion over other services. Published in @jamanetworkopen.com.

https://bit.ly/4k6hl8d

#HemOnc

Significant Barriers to Health Literacy Exist for Patients With Thalassemia Researchers determined there may be overestimation of disease understanding and barriers to health literacy among patients with thalassemia.

"Many patient populations with hereditary conditions such as #thalassemia have lived w the disease for their entire life, so it’s not surprising that they report high levels of confidence in health-related knowledge" @devasharma.bsky.social of @vumedicine.bsky.social.

https://bit.ly/4t4hyN6

#ASH25

Regular ADAMTS13 Prophylaxis Reduces Acute Events and Organ Damage in cTTP Researchers determined regular ADAMTS13 prophylaxis reduces acute episodes and prevents end-organ damage in cTTP.

A long-term analysis from the UK TTP Registry, published in @bloodjournals.hematology.org, shows that regular ADAMTS13 prophylaxis reduces acute episodes and prevents end-organ damage in congenital thrombotic #thrombocytopenicPurpura.

https://bit.ly/49Ncnse

#cTTP